AJR InPractice
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Callahan, R. J.
Right arrow Articles by Weissleder, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Callahan, R. J.
Right arrow Articles by Weissleder, R.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

American Journal of Roentgenology, Vol 171, 137-143, Copyright © 1998 by American Roentgen Ray Society

ARTICLES

Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging

RJ Callahan, A Bogdanov Jr, AJ Fischman, TJ Brady and R Weissleder
Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown 02129, USA.

OBJECTIVE: To obtain initial data on the safety and efficacy of a novel polymeric, synthetic blood pool contrast agent [O- monomethoxypoly(ethylene glycol)-O'succinyl]poly(N-epsilon-L-lysyl [99mTc]diethylenetriamine pentaacetate monoamide, we performed a preclinical evaluation and phase 1 clinical trial under an investigator- sponsored investigational new drug application. MATERIALS AND METHODS: Methoxypoly(ethylene glycol)ethylenetriaminopentaacetic acid was formulated into a kit containing the polymer, stannous chloride, and a buffer. Kits were stored in frozen form for subsequent labeling with technetium-99m. Acute and subacute toxicity studies were carried out in rats and rabbits. Healthy human volunteers (n = 6) were then enrolled in a prospective, open-label phase 1 clinical study. RESULTS: Animal studies showed no signs of acute or subacute toxicity at doses 280 times the proposed dose for humans. In the clinical trial with humans, no significant abnormalities of laboratory values, ECG findings, or hemodynamic parameters were seen. One volunteer experienced facial flushing and palpitations. Four volunteers showed typical blood pool biodistribution, with a blood half-life of 20.6 +/- 2.3 hr. At 24 hr after administration, 22.1% +/- 2.5% of the injected dose had been excreted through the kidneys. Two other volunteers showed a different biodistribution (primarily to liver and spleen), presumably associated with labeling instability. CONCLUSION: Synthetic methoxypoly(ethylene glycol)-grafted polymers can have long circulation times in humans. Pharmaceuticals based on such polymers are expected to have clinical applications in cardiovascular imaging, gastrointestinal bleeding studies, and capillary leak imaging.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 CirculationHome page
F. A. Jaffer, C. Vinegoni, M. C. John, E. Aikawa, H. K. Gold, A. V. Finn, V. Ntziachristos, P. Libby, and R. Weissleder
Real-Time Catheter Molecular Sensing of Inflammation in Proteolytically Active Atherosclerosis
Circulation, October 28, 2008; 118(18): 1802 - 1809.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
X. Montet, J.-L. Figueiredo, H. Alencar, V. Ntziachristos, U. Mahmood, and R. Weissleder
Tomographic Fluorescence Imaging of Tumor Vascular Volume in Mice
Radiology, March 1, 2007; 242(3): 751 - 758.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, K. A. Krohn, S. M. Larson, R. Weissleder, D. A. Mankoff, J. M. Hoffman, J. M. Link, K. Z. Guyton, W. C. Eckelman, H. I. Scher, et al.
The Progress and Promise of Molecular Imaging Probes in Oncologic Drug Development
Clin. Cancer Res., November 15, 2005; 11(22): 7967 - 7985.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Tang, M. Kim, D. Carrasco, A. L. Kung, L. Chin, and R. Weissleder
In vivo Assessment of RAS-Dependent Maintenance of Tumor Angiogenesis by Real-time Magnetic Resonance Imaging
Cancer Res., September 15, 2005; 65(18): 8324 - 8330.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Shah, C.-H. Tung, C.-H. Chang, E. Slootweg, T. O'Loughlin, X. O. Breakefield, and R. Weissleder
In Vivo Imaging of HIV Protease Activity in Amplicon Vector-transduced Gliomas
Cancer Res., January 1, 2004; 64(1): 273 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
U. Mahmood and R. Weissleder
Near-Infrared Optical Imaging of Proteases in Cancer
Mol. Cancer Ther., May 1, 2003; 2(5): 489 - 496.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
C. Bremer, M. Mustafa, A. Bogdanov Jr, V. Ntziachristos, A. Petrovsky, and R. Weissleder
Steady-State Blood Volume Measurements in Experimental Tumors with Different Angiogenic Burdens--A Study in Mice
Radiology, January 1, 2003; 226(1): 214 - 220.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-H. Tung, U. Mahmood, S. Bredow, and R. Weissleder
In Vivo Imaging of Proteolytic Enzyme Activity Using a Novel Molecular Reporter
Cancer Res., September 1, 2000; 60(17): 4953 - 4958.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Roentgen Ray Society.